PRFX
PRF Technologies Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.03
P/S
0.00
EV/EBITDA
0.95
DCF Value
$6.43
FCF Yield
-1949.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.0%
ROA
-26.7%
ROIC
-33.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $17.0K | $-4.8M | $-7.47 |
| Q2 2025 | $0.00 | $-1.2M | $-13.75 |
| Q1 2025 | $0.00 | $-1.2M | $-13.75 |
| Q4 2024 | $0.00 | $-885.0K | $-15.00 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
0.71
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.